Immunome (IMNM) Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Does the media favor ACAD or IMNM?

In the previous week, Immunome had 13 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 27 mentions for Immunome and 14 mentions for ACADIA Pharmaceuticals. Immunome's average media sentiment score of 0.78 beat ACADIA Pharmaceuticals' score of 0.61 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	8 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, ACAD or IMNM?

ACADIA Pharmaceuticals has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$957.80M	2.98	-$61.29M	$1.36	12.57
Immunome	$9.04M	67.32	-$106.81M	-$5.17	-1.35

Does the MarketBeat Community prefer ACAD or IMNM?

ACADIA Pharmaceuticals received 860 more outperform votes than Immunome when rated by MarketBeat users. However, 77.08% of users gave Immunome an outperform vote while only 73.05% of users gave ACADIA Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
ACADIA Pharmaceuticals	Outperform Votes 897 73.05%	Underperform Votes 331 26.95%
Immunome	Outperform Votes 37 77.08%	Underperform Votes 11 22.92%

Do institutionals and insiders hold more shares of ACAD or IMNM?

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of Immunome shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has more risk and volatility, ACAD or IMNM?

ACADIA Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500.

Do analysts recommend ACAD or IMNM?

ACADIA Pharmaceuticals currently has a consensus target price of $23.93, indicating a potential upside of 39.96%. Immunome has a consensus target price of $25.50, indicating a potential upside of 264.29%. Given Immunome's stronger consensus rating and higher possible upside, analysts plainly believe Immunome is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Immunome	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is ACAD or IMNM more profitable?

ACADIA Pharmaceuticals has a net margin of 13.83% compared to Immunome's net margin of -3,014.59%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	13.83%	25.83%	14.71%
Immunome	-3,014.59%	-48.63%	-41.62%

Summary

ACADIA Pharmaceuticals beats Immunome on 11 of the 18 factors compared between the two stocks.